Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06635785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT06635785
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- OncoC4, Inc.
- Industry
- Enrollment
- 387 participants
Conditions and interventions
Conditions
Interventions
- AI-081 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2025
- Primary completion
- Jun 29, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Apr 8, 2026
2025 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | Recruiting |
| University of Florida UF Health Cancer Center | Gainesville | Florida | 32610 | Recruiting |
| Memorial Healthcare System | Hollywood | Florida | 33021 | Recruiting |
| Ocala Oncology Center PL DBA Florida Cancer Affiliates | Ocala | Florida | 34474 | Recruiting |
| AdventHealth Cancer Institute | Orlando | Florida | 32804 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| Norton Cancer Center | Louisville | Kentucky | 40202 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | 48109 | Recruiting |
| Henry Ford Health | Detroit | Michigan | 48202 | Recruiting |
| The Tisch Cancer Institute, Mount Sinai Medical Center | New York | New York | 10029 | Not yet recruiting |
| University of North Carolina at Chapel Hill Cancer Center | Chapel Hill | North Carolina | 27599 | Recruiting |
| Novant Health Cancer Institute | Winston-Salem | North Carolina | 27103 | Recruiting |
| The Ohio State University James Cancer Center | Columbus | Ohio | 43210 | Recruiting |
| Prisma Health | Greenville | South Carolina | 29605 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| University of Utah Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06635785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06635785 live on ClinicalTrials.gov.